---
search:
  boost: 3
---

# Movement Disorders

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [CNS - Movement Disorders - Austedo](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURVU0TFM4UEVZT0FVQVkwVDJHMTVHUFBPSSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Movement Disorders - Ingrezza, Tetrabenazine](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQzBZOVJMRloyT0RUT1cxM0kwOEJYUVhPUSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                   | Generic Name | Quantity | Time (Days) |
| :-------------------------- | :----------- | :------: | :---------: |
| Austedo <sup>PA ST</sup>    |              |          |             |
| Ingrezza <sup>PA</sup>      |              |          |             |
| Tetrabenazine <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
|               |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Must be prescribed by or in consultation with a neurologist or psychiatrist

### Step Therapy

Step Therapy Approval Criteria

Must have an inadequate clinical response of at least ^^90 days^^ to a maximally
tolerated dose of tetrabenazine for Huntingtonâ€™s Disease only

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^two preferred^^ drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=35&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} 

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001+UPDL+Criteria+_v2.FINAL.pdf#page=41){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001_UPDL_V2.FINAL.hyperlinks_added.pdf#page=17){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
